Canaccord Genuity initiated coverage of Niagen Bioscience with a rating of Buy and set a new price target of $13.00

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

SCHEDULE 13G/A - Niagen Bioscience, Inc. (0001386570) (Subject)

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

10-Q - Niagen Bioscience, Inc. (0001386570) (Filer)

SCHEDULE 13G - Niagen Bioscience, Inc. (0001386570) (Subject)

8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)

S-8 - Niagen Bioscience, Inc. (0001386570) (Filer)

Divestiture streamlines operations and advances the Company's strategy to fully exit non-core activities Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience's operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction

Patent strengthens Niagen Bioscience's intellectual property moat in fast-growing NAD+-boosting IV and injectable delivery formats, supporting commercial expansion and deterring infringers Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the broadening of its NAD+ precursor intellectual property (IP) portfolio with the newly granted U.S. Patent No. 12,558,367, which covers the methods of use of nicotinamide riboside (NR) and derivatives in intravenous and injectable formulations. Rob Fried, CEO of Niagen Bioscience, commented, "This patent expands our intellectual propert

Taking place March 23-25, 2026, this three-day scientific forum will convene the world's foremost NAD experts in Copenhagen to advance evidence-based dialogue and accelerate clinical translation Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces it is the headlining sponsor of the inaugural NAD for Health: Opportunities & Challenges scientific meeting hosted by the University of Copenhagen, taking place March 23–25, 2026 at the Royal Danish Academy of Sciences and Letters in central Copenhagen. Space is limited and registration is required; see registration details at the end

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, March 4, 2026. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the fourth quarter and fiscal year 2025 financial results and provide a general business update on W

Qualified Customers may now purchase Tru Niagen at www.truniagen.com using HSA/FSA funds with a Truemed Letter of Medical Necessity (LMN) Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it has partnered with Truemed to provide qualified customers the option to purchase Tru Niagen®, the number one NAD+ supplement in the United States*, using Health Savings Account (HSA) and Flexible Spending Account (FSA) funds on its direct-to-consumer website, www.truniagen.com. Qualified customers may use HSA/FSA funds to purchase Tru Niagen with a Truemed Letter of Medical Necessit

This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industry Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen's University Belfast (QUB), further strengthening the Company's long-standing leadership and ownership position in NAD+ precursor intellectual property. The acquired portfolio comprises the core body of patents underpinning the productio

Findings show a significant increase in NAD+ levels and within-group benefits in fatigue, depression, and sleep quality Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today shared promising results from the first-of-its-kind clinical trial published today in The Lancet peer-reviewed journal eClinicalMedicine demonstrating that daily supplementation with Niagen®, Niagen Bioscience's patented nicotinamide riboside (NR) ingredient, significantly increased NAD+ levels and improved executive functioning, fatigue, depression, and sleep quality, when compared to their baseline levels, in some i

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Board of Directors has approved a share repurchase program under which the Company is authorized to repurchase up to $10 million of outstanding common stock over approximately 24 months (the "Program"). "We believe Niagen Bioscience is an excellent investment and the Program is a compelling use of the company's capital presently," said Rob Fried, Chief Executive Officer of Niagen Bioscience. Under the Program, Niagen Bioscience may repurchase shares in the open market, through privately negotiated transactions or oth

Net sales increased 33% to $34.0 million Gross margin increased 100 bps to 64.5% Net income of $4.6 million, up $2.7 million from the prior year Adjusted EBITDA increased by 120% to $6.4 million Full year 2025 net sales outlook of 25% to 30% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%. Gross margin increased 100 basis points to 64.5%. Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points.

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November 4, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the third quarter 2025 financial results and provide a general business update on Tuesday, November 4, 2025, at 4:

Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).​ Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology

Divestiture streamlines operations and advances the Company's strategy to fully exit non-core activities Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex Reference Standards business to LGC, as of February 24, 2026, in an all-cash transaction. The divestiture further streamlines Niagen Bioscience's operations, advances the Company's strategy to exit non-core activities, and focuses resources on NAD+ science, intellectual property, and commercial growth within the longevity industry. Rob Fried, CEO of Niagen Bioscience, remarked, "This transaction

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, March 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fourth quarter and fiscal year 2025, which ended December 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, March 4, 2026. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the fourth quarter and fiscal year 2025 financial results and provide a general business update on W

This acquisition establishes Niagen Bioscience as the sole owner of the most comprehensive and defensible intellectual property portfolio in the NAD+ industry Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that it has acquired a comprehensive portfolio of existing patents covering nicotinamide riboside (NR) and its salt forms from Queen's University Belfast (QUB), further strengthening the Company's long-standing leadership and ownership position in NAD+ precursor intellectual property. The acquired portfolio comprises the core body of patents underpinning the productio

Net sales increased 33% to $34.0 million Gross margin increased 100 bps to 64.5% Net income of $4.6 million, up $2.7 million from the prior year Adjusted EBITDA increased by 120% to $6.4 million Full year 2025 net sales outlook of 25% to 30% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the third quarter of 2025. Third Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 33% to $34.0 million, with Tru Niagen® sales of $26.0 million, up 44%. Gross margin increased 100 basis points to 64.5%. Sales and marketing expense as a percentage of net sales was 25.8%, an improvement of 170 basis points.

Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Tuesday, November 4, 2025, at 4:30 p.m. ET to discuss its financial results for the third quarter 2025, which ended September 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Tuesday, November 4, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the third quarter 2025 financial results and provide a general business update on Tuesday, November 4, 2025, at 4:

Net sales increased 37% to $31.1 million Gross margin increased 480 basis points to 65.0% Net income of $3.6 million versus breakeven in prior year period Adjusted EBITDA increased by 221% to $5.0 million Raising full year 2025 revenue outlook to 22% to 27% year-over-year growth Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the second quarter of 2025. Second Quarter 2025 Financial Highlights Compared to Prior Year Period Total net sales increased 37% to $31.1 million, with Tru Niagen® sales reaching $22.7 million, growing 22%. Niagen® ingredient sales increased 135% to $7.4 million including food-grade and pharmaceutical-grade. Gross margin

Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, August 6, at 4:30 p.m. ET to discuss its financial results for the second quarter 2025, which ended June 30, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, August 6, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the second quarter 2025 financial results and provide a general business update on Wednesday, Aug

Total net sales of $30.5 million, up $8.3 million or 38% year-over-year, gross margin of 63.4%, net income of $5.1 million and Adjusted EBITDA of $4.9 million for the three months ended March 31, 2025 and increased full year 2025 outlook. Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2025. First Quarter 2025 Financial and Recent Operational Highlights Total net sales were $30.5 million, with $21.5 million from Tru Niagen®, up 38%, and 24%, respectively, from the prior year quarter. Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $8.0 million, up 95% YoY. Delivered strong gross margin of 63.4%,

Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announces that it will hold a conference call on Wednesday, May 7, 2025, at 4:30 p.m. ET to discuss its financial results for the first quarter 2025, which ended March 31, 2025. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 7, 2025. Investor Conference Call: Niagen Bioscience management will host an investor conference call to discuss the first quarter 2025 financial results and provide a general business update on Wednesday, May 7,